New chemo cocktail shows promise for pancreatic cancer patients before surgery
NCT ID NCT06423326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline removable. The goal is to see if this approach is safe and effective, potentially leading to better results than surgery alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene test may guide smarter chemo for pancreatic cancer
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Could a special MRI help doctors better treat pancreatic cancer?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Triple attack on pancreatic cancer: radiotherapy, chemo, and immunotherapy aim to make tumors removable
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?